J&J changes heart drug label to show mortality risk

	Tweet

Johnson & Johnson on Monday said it had revised the label of its Natrecor (nesiritide) to indicate it increased the risk of death within 30 days after patients were treated with it for heart failure, compared with standard treatments.

The lengthy new section on “Effect on Mortality” in the package insert label says 5.3 percent of patients taking Natrecor in seven studies died, compared with 4.3 percent of those taking other medicines.

Although the collective data from the studies reflects a 23-percent higher death rate for those taking Natrecor, J&J spokesman Doug Arbesfeld said the number of patients in the studies was too small to produce conclusive results of death risk. 

RELATED STORIES:
Parkinson’s Drugs Tradeoff: Better Muscle Control, Worse Side Effects   Anticholinergic drugs may lead to mild mental impairment in elderly   US report faults FDA post-approval study tracking   New drug approved for childhood leukemia   Asthma, Emphysema Drug May Weaken Bones   UK lawmakers slam slack pharmaceutical regulation   Vertex says drug quickly treats hepatitis C   Diabetes drug shows promise in multiple sclerosis   FDA Says Consumers Continue to Buy Risky Drugs Online   FDA approves limited use of artificial heart   Tamiflu best for bird flu, but avoid steroids   FDA finds fake, subpotent drugs online

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]